Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Alzinova

0.42 SEK-0.47 %23.10. klo 18.25
Less than 1K followers

ALZ

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
-0.47 %
+5.35 %
-37.40 %
-24.28 %
-47.29 %
-69.10 %
-78.51 %
-91.94 %
-93.91 %

Alzinova is a biotechnology company. The company specializes in the therapeutic treatment of Alzheimer's and conducts research and development of peptides that are further developed as vaccines. In addition, the company also develops various research tools within the field of work. The largest operations are found in the Nordic market. The company was founded in 2011 and has its headquarters in Mölndal.

Read more
Market cap
133.85M SEK
Turnover
227.65K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
12.11.
2026

Interim report Q3'26

25.2.
2027

Annual report '26

All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release21.10.2026 klo 12.20

Alzinova finalises selection of seven US clinical sites as ADVANCE Phase 2a study moves toward first participant enrolment

Alzinova
Regulatory press release20.10.2026 klo 08.30

Alzinova’s Board of Directors resolves on a directed issue of units to underwriters in connection with the completed rights issue

Alzinova
Press release08.10.2026 klo 17.46

Redeye: Alzinova: Rights issue subscribed to 86.2%

Alzinova

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release08.10.2026 klo 17.05

Alzinova to present latest developments in ALZ-101 and blood-based diagnostics at Redeye Neurology Day

Alzinova
Press release08.10.2026 klo 09.00

DNB Carnegie Access: Alzinova: Rights issue completed

Alzinova
Regulatory press release07.10.2026 klo 20.25

Alzinova announces final outcome of the rights issue

Alzinova
Regulatory press release06.10.2026 klo 18.46

Alzinova announces preliminary outcome of the rights issue

Alzinova
Regulatory press release01.10.2026 klo 19.25

Alzinova broadens its shareholder base with a new institutional investor, while its principal shareholder subscribes for its full pro rata share in the ongoing rights issue

Alzinova
Regulatory press release01.10.2026 klo 09.30

The last day of trading in unit rights in Alzinova’s rights issue

Alzinova
Press release01.10.2026 klo 09.27

DNB Carnegie Access: Alzinova: Supportive early results for diagnostics programme

Alzinova
Regulatory press release30.09.2026 klo 12.45

Alzinova completes study with Amsterdam UMC – results support continued development and partnership discussions in blood-based Alzheimer’s diagnostics

Alzinova
Press release24.09.2026 klo 17.30

Alzinova’s Phase II study with ALZ-101 accepted for presentation at international Alzheimer’s conference

Alzinova
Regulatory press release22.09.2026 klo 09.30

The subscription period in Alzinovas rights issue of units starts today

Alzinova
Regulatory press release18.09.2026 klo 09.30

Alzinova publishes information memorandum in connection with rights issue of units

Alzinova
Press release11.09.2026 klo 14.52

Redeye: Alzinova: Phase II study update and SEK51 rights issue

Alzinova
Press release11.09.2026 klo 11.20

DNB Carnegie Access: Alzinova: ALZ-101 enters Phase II start-up as Alzinova raises capital

Alzinova
Regulatory press release10.09.2026 klo 22.10

The Board of Directors of Alzinova resolves on a rights issue of units of approximately SEK 51 million

Alzinova
Regulatory press release10.09.2026 klo 22.05

Alzinova initiates operational start-up of global Phase 2 study with ALZ-101

Alzinova
Press release24.08.2026 klo 11.02

DNB Carnegie Access: Alzinova: Diagnostics readout next, partner process delayed – Q2 review

Alzinova
Press release20.08.2026 klo 14.24

Redeye: Alzinova (Q2 Review): Capitalizing on diagnostics opportunities

Alzinova